RBM4B

Across TCGA pan-cancer cohorts, RBM4B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RBM4B data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RBM4B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RBM4B expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

LUAD, UCEC, and CCRCC are the cancer types where RBM4B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.210	0.778	.001	25	view →
UCEC	DFS	Median	III,IV	0.297	0.902	.018	24	view →
CCRCC	DFS	Median	III,IV	0.863	0.542	.003	15	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RBM4B–LUAD (OS)

Open the LUAD breakdown →